Yahoo
KSE - Delayed Quote KRW

Daewoong Pharmaceutical Co., Ltd (069620.KS)

102,300.00 +1,200.00 (+1.19%)
As of 9:12:28 AM GMT+9. Market Open.
Chart Range Bar
Loading chart for 069620.KS
  • Previous Close 101,100.00
  • Open 100,000.00
  • Bid 101,900.00 x --
  • Ask 102,300.00 x --
  • Day's Range 100,000.00 - 102,300.00
  • 52 Week Range 98,400.00 - 199,400.00
  • Volume 1,293
  • Avg. Volume 22,037
  • Market Cap (intraday) 1.177T
  • Beta (5Y Monthly) 0.00
  • PE Ratio (TTM) --
  • EPS (TTM) --
  • Earnings Date (est.) --
  • Forward Dividend & Yield 600.00 (0.59%)
  • Ex-Dividend Date Dec 29, 2025
  • 1y Target Est 201,000.00

Daewoong Pharmaceutical Co., Ltd. develops, manufactures and commercializes pharmaceutical products in South Korea and internationally. It offers products in therapeutic areas, such as central nervous system, endocrinology, musculoskeletal, nephrology, antineoplastic, cardiovascular, gastrointestinal, metabolic, antiviral, analgesic, antacid, and digestive diseases, as well as wound, iron supplements, and muti-vitamins. The company also provides COVID-19 PCR kit, COVID-19 IgG/IgM RDT, and viral transport medium medical devices. The company was founded in 1945 and is headquartered in Seoul, South Korea.

www.daewoong.com

1,893

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Recent News

View More

Performance Overview

Trailing total returns as of 11/2/2026, which may include dividends or other distributions. Benchmark is KOSPI Composite Index (^KS11) .

YTD Return

069620.KS
40.63%
KOSPI Composite Index (^KS11)
34.09%

1-Year Return

069620.KS
26.36%
KOSPI Composite Index (^KS11)
37.57%

3-Year Return

069620.KS
0.35%
KOSPI Composite Index (^KS11)
141.16%

5-Year Return

069620.KS
28.05%
KOSPI Composite Index (^KS11)
87.51%

Earnings Trends

View More

Earnings Per Share

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q2 FY26
Revenue 400.19B
Earnings 69.4B
Profit Margin 17.34%

Q3

FY25

Q4

FY25

Q1

FY26

Q2

FY26

0
100B
200B
300B
400B
10.0%
15.0%
20.0%

Analyst Insights

View More

Analyst Price Targets

180,000.00
201,000.00 Average
102,300.00 Current
220,000.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Statistics

View More

Valuation Measures

Annual
  • Market Cap

  • Enterprise Value

  • Trailing P/E

  • Forward P/E

  • PEG Ratio (current)

  • Price/Sales (ttm)

  • Price/Book (mrq)

  • Enterprise Value/Revenue

  • Enterprise Value/EBITDA

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    11.95%

  • Return on Assets (ttm)

    5.09%

  • Return on Equity (ttm)

    16.64%

  • Revenue (ttm)

    1.64T

  • Net Income Avi to Common (ttm)

    195.47B

  • Diluted EPS (ttm)

    --

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    158.42B

  • Total Debt/Equity (mrq)

    77.64%

  • Levered Free Cash Flow (ttm)

    -174.76B

Company Insights

Research Reports

View More

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: